Abstract
This is the fourth article in a four-part series on new radiopharmaceuticals. Upon completion of this article, the reader should be able to (1) recognize the need for assessment of radiochemical purity, (2) describe some of the available systems, and (3) be aware of common errors in performing quality control on the newer radiopharmaceuticals.
